These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35653195)

  • 21. APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.
    Giammanco A; Spina R; Cefalù AB; Averna M
    Curr Atheroscler Rep; 2023 Mar; 25(3):67-76. PubMed ID: 36689070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
    Spagnuolo CM; Hegele RA
    Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of hypertriglyceridemia by two diets rich either in unsaturated fatty acids or in carbohydrates: effects on lipoprotein subclasses, lipolytic enzymes, lipid transfer proteins, insulin and leptin.
    Pieke B; von Eckardstein A; Gülbahçe E; Chirazi A; Schulte H; Assmann G; Wahrburg U
    Int J Obes Relat Metab Disord; 2000 Oct; 24(10):1286-96. PubMed ID: 11093290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
    Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
    J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
    [No Abstract]   [Full Text] [Related]  

  • 25. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
    Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ
    Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism.
    Ramms B; Gordts PLSM
    Curr Opin Lipidol; 2018 Jun; 29(3):171-179. PubMed ID: 29547399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unanticipated Enhancement of Intestinal TG Output by Apoc3 ASO Inhibition.
    Syed-Abdul MM; Tian L; Lewis GF
    Arterioscler Thromb Vasc Biol; 2023 Nov; 43(11):2133-2142. PubMed ID: 37675633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
    Tardif JC; Karwatowska-Prokopczuk E; Amour ES; Ballantyne CM; Shapiro MD; Moriarty PM; Baum SJ; Hurh E; Bartlett VJ; Kingsbury J; Figueroa AL; Alexander VJ; Tami J; Witztum JL; Geary RS; O'Dea LSL; Tsimikas S; Gaudet D
    Eur Heart J; 2022 Apr; 43(14):1401-1412. PubMed ID: 35025993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin-binding EGF-like growth factor (HB-EGF) antisense oligonucleotide protected against hyperlipidemia-associated atherosclerosis.
    Kim S; Graham MJ; Lee RG; Yang L; Kim S; Subramanian V; Layne JD; Cai L; Temel RE; Shih D; Lusis AJ; Berliner JA; Lee S
    Nutr Metab Cardiovasc Dis; 2019 Mar; 29(3):306-315. PubMed ID: 30738642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice.
    Distel E; Barrett TJ; Chung K; Girgis NM; Parathath S; Essau CC; Murphy AJ; Moore KJ; Fisher EA
    Circ Res; 2014 Oct; 115(9):759-69. PubMed ID: 25201910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
    Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
    N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting ApoC-III to Reduce Coronary Disease Risk.
    Khetarpal SA; Qamar A; Millar JS; Rader DJ
    Curr Atheroscler Rep; 2016 Sep; 18(9):54. PubMed ID: 27443326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies.
    Dib I; Khalil A; Chouaib R; El-Makhour Y; Noureddine H
    Mol Biol Rep; 2021 Jan; 48(1):875-886. PubMed ID: 33389539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III.
    Ooi EM; Chan DC; Hodson L; Adiels M; Boren J; Karpe F; Fielding BA; Watts GF; Barrett PH
    Eur J Clin Invest; 2016 Aug; 46(8):730-6. PubMed ID: 27378472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.
    Ooi EM; Barrett PH; Chan DC; Watts GF
    Clin Sci (Lond); 2008 May; 114(10):611-24. PubMed ID: 18399797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
    Zheng C; Khoo C; Furtado J; Sacks FM
    Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins.
    Furtado JD; Wedel MK; Sacks FM
    J Lipid Res; 2012 Apr; 53(4):784-91. PubMed ID: 22301884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.
    Packard CJ; Pirillo A; Tsimikas S; Ference BA; Catapano AL
    Cardiovasc Res; 2024 Feb; 119(18):2843-2857. PubMed ID: 38039351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis.
    Liu C; Schönke M; Zhou E; Li Z; Kooijman S; Boon MR; Larsson M; Wallenius K; Dekker N; Barlind L; Peng XR; Wang Y; Rensen PCN
    Cardiovasc Res; 2022 Jan; 118(2):489-502. PubMed ID: 33693480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
    Alexander VJ; Xia S; Hurh E; Hughes SG; O'Dea L; Geary RS; Witztum JL; Tsimikas S
    Eur Heart J; 2019 Sep; 40(33):2785-2796. PubMed ID: 31329855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.